NO20065503L - Indolyderivater som lever-X-resptormodulatorer. - Google Patents
Indolyderivater som lever-X-resptormodulatorer.Info
- Publication number
- NO20065503L NO20065503L NO20065503A NO20065503A NO20065503L NO 20065503 L NO20065503 L NO 20065503L NO 20065503 A NO20065503 A NO 20065503A NO 20065503 A NO20065503 A NO 20065503A NO 20065503 L NO20065503 L NO 20065503L
- Authority
- NO
- Norway
- Prior art keywords
- liver
- receptor modulators
- indole derivatives
- compounds
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forbindelser med formel (I) og farmasøytisk akseptable salter og farmasøytisk akseptable estere derav, hvor R1, R2, R3, R4, R5, R6, A, m, n og p er som definert i krav 1. Disse forbindelsene kan anvendes som medikamenter.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04101889 | 2004-05-03 | ||
PCT/EP2005/004454 WO2005105791A1 (en) | 2004-05-03 | 2005-04-26 | Indolyl derivatives as liver-x-receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065503L true NO20065503L (no) | 2007-01-24 |
Family
ID=34970495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065503A NO20065503L (no) | 2004-05-03 | 2006-11-29 | Indolyderivater som lever-X-resptormodulatorer. |
Country Status (26)
Country | Link |
---|---|
US (2) | US7173048B2 (no) |
EP (1) | EP1756096B1 (no) |
JP (1) | JP4682192B2 (no) |
KR (1) | KR100893449B1 (no) |
CN (1) | CN1950365A (no) |
AR (1) | AR049497A1 (no) |
AT (1) | ATE439357T1 (no) |
AU (1) | AU2005238176B2 (no) |
BR (1) | BRPI0510599A (no) |
CA (1) | CA2564563C (no) |
DE (1) | DE602005015962D1 (no) |
DK (1) | DK1756096T3 (no) |
ES (1) | ES2329489T3 (no) |
HR (1) | HRP20090533T1 (no) |
IL (1) | IL178767A0 (no) |
MX (1) | MXPA06012683A (no) |
MY (1) | MY139571A (no) |
NO (1) | NO20065503L (no) |
NZ (1) | NZ550447A (no) |
PL (1) | PL1756096T3 (no) |
PT (1) | PT1756096E (no) |
RU (1) | RU2368612C2 (no) |
SI (1) | SI1756096T1 (no) |
TW (1) | TWI287537B (no) |
WO (1) | WO2005105791A1 (no) |
ZA (1) | ZA200608886B (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US8399666B2 (en) * | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
ES2581765T3 (es) | 2006-08-24 | 2016-09-07 | University Of Tennessee Research Foundation | Acilanilidas sustituidas y métodos de uso de las mismas |
EP2079466B1 (en) * | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
WO2008137435A1 (en) * | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
EP2152707B1 (en) | 2007-05-04 | 2012-06-20 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
KR20100051814A (ko) * | 2007-07-17 | 2010-05-18 | 브리스톨-마이어스 스큅 컴퍼니 | Gpr119 g 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물 |
KR100918814B1 (ko) * | 2007-10-04 | 2009-09-25 | 건국대학교 산학협력단 | 인쇄방법을 이용한 세라믹 전자부품 고속제조방법 |
TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
EP2254907A1 (en) * | 2008-03-17 | 2010-12-01 | F. Hoffmann-La Roche AG | Lxr ligand binding domain (lxr lbd) crystals |
US20110160249A1 (en) * | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US8415367B2 (en) | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
US8729084B2 (en) | 2010-05-06 | 2014-05-20 | Bristol-Myers Squibb Company | Benzofuranyl analogues as GPR119 modulators |
BR112012028445A2 (pt) | 2010-05-06 | 2016-07-19 | Bristol Myers Squibb Co | compostos de heteroarila bicíclica como moduladores de gpr119 |
WO2012097744A1 (en) * | 2011-01-20 | 2012-07-26 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
US9174965B2 (en) | 2012-05-16 | 2015-11-03 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators |
LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
EP2970119B1 (en) * | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015061272A1 (en) | 2013-10-22 | 2015-04-30 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
KR102513342B1 (ko) | 2016-07-22 | 2023-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코키나제 활성화제 및 그의 사용 방법 |
WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
CN115028655B (zh) * | 2022-05-20 | 2024-01-16 | 上海大学 | 一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE45227B1 (en) * | 1976-06-24 | 1982-07-14 | Du Pont | Carbostyrils |
US4251659A (en) * | 1977-12-22 | 1981-02-17 | E. I. Du Pont De Nemours And Company | Polyfluorohydroxyisopropyl-heterocyclic compounds |
JPH0995482A (ja) | 1995-09-29 | 1997-04-08 | Shionogi & Co Ltd | α−置換酢酸を有する複素環誘導体、その製造用中間体ならびにそれを含有する農薬 |
WO1997019311A1 (en) | 1995-11-17 | 1997-05-29 | Form Rite | Bypass fitting for a transmission fluid cooler |
KR100654516B1 (ko) | 2001-05-15 | 2006-12-05 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료에서 ppar-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체 |
US6472386B1 (en) * | 2001-06-29 | 2002-10-29 | Kowa Co., Ltd. | Cyclic diamine compound with 5-membered ring groups |
GB0216224D0 (en) | 2002-07-12 | 2002-08-21 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-04-26 DK DK05751959T patent/DK1756096T3/da active
- 2005-04-26 EP EP05751959A patent/EP1756096B1/en active Active
- 2005-04-26 BR BRPI0510599-4A patent/BRPI0510599A/pt not_active IP Right Cessation
- 2005-04-26 DE DE602005015962T patent/DE602005015962D1/de active Active
- 2005-04-26 RU RU2006142746/04A patent/RU2368612C2/ru not_active IP Right Cessation
- 2005-04-26 CA CA2564563A patent/CA2564563C/en not_active Expired - Fee Related
- 2005-04-26 ES ES05751959T patent/ES2329489T3/es active Active
- 2005-04-26 CN CNA2005800142069A patent/CN1950365A/zh active Pending
- 2005-04-26 AT AT05751959T patent/ATE439357T1/de active
- 2005-04-26 PT PT05751959T patent/PT1756096E/pt unknown
- 2005-04-26 KR KR1020067023014A patent/KR100893449B1/ko not_active IP Right Cessation
- 2005-04-26 SI SI200530765T patent/SI1756096T1/sl unknown
- 2005-04-26 AU AU2005238176A patent/AU2005238176B2/en not_active Ceased
- 2005-04-26 MX MXPA06012683A patent/MXPA06012683A/es active IP Right Grant
- 2005-04-26 PL PL05751959T patent/PL1756096T3/pl unknown
- 2005-04-26 JP JP2007511949A patent/JP4682192B2/ja not_active Expired - Fee Related
- 2005-04-26 NZ NZ550447A patent/NZ550447A/en not_active IP Right Cessation
- 2005-04-26 WO PCT/EP2005/004454 patent/WO2005105791A1/en active Application Filing
- 2005-04-27 US US11/115,942 patent/US7173048B2/en not_active Expired - Fee Related
- 2005-04-28 MY MYPI20051897A patent/MY139571A/en unknown
- 2005-04-29 AR ARP050101717A patent/AR049497A1/es unknown
- 2005-04-29 TW TW094113966A patent/TWI287537B/zh not_active IP Right Cessation
-
2006
- 2006-10-19 IL IL178767A patent/IL178767A0/en unknown
- 2006-10-25 ZA ZA200608886A patent/ZA200608886B/en unknown
- 2006-11-29 NO NO20065503A patent/NO20065503L/no not_active Application Discontinuation
- 2006-12-11 US US11/636,925 patent/US7485652B2/en not_active Expired - Fee Related
-
2009
- 2009-10-02 HR HR20090533T patent/HRP20090533T1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065503L (no) | Indolyderivater som lever-X-resptormodulatorer. | |
NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
NO20082561L (no) | Nye koblede pyrrolderivater | |
NO20082388L (no) | Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer | |
NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
WO2006010546A3 (en) | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors | |
TW200745032A (en) | Novel heterobicyclic derivatives | |
NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
NO20054852L (no) | GFAT inhibitorer | |
NO20073551L (no) | Nikotinacetylkolinreseptorligander | |
NO20044866L (no) | Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer | |
ATE417049T1 (de) | Biaryldiazabicycloalkanamide als nicotinische acetylcholinagonisten | |
NO20082159L (no) | Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser | |
TW200740758A (en) | Benzoquinazoline derivatives | |
NO20092314L (no) | Benzamidderivater som EP4 receptoragonister | |
MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
TW200607799A (en) | Therapeutic compounds: pyridine as scaffold | |
NO20065904L (no) | Terapeutiske forbindelser | |
NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
NO20071658L (no) | Alkil-pyridiner som 11-beta-inhibitorer for diabetes | |
NO20084915L (no) | Nikotinacetylcholinreseptorligander 101 | |
NO20080554L (no) | Pyrazolonderivater | |
NO20065873L (no) | 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner | |
WO2007068728A3 (en) | N-substituted pyrrolopyridinones active as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |